Tushar Shah

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

RareGen LLC provides strategy, investment, and commercialization for rare disease pharmaceutical products. The company is headquartered in Durham, NC.

Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

PBM Capital Group LLC (PBM Capital Group) is a private equity and venture capital firm founded in 2010 by Paul B. Manning. The firm is headquartered in Charlottesville, Virginia.

Canaan Management, Inc. (Canaan Management) is a venture capital firm founded in 1987 by Eric A. Young. The firm is headquartered in Westport, CT.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Gen9, Inc. engages in the development of synthetic biology technologies. It transforms synthetic biology by creating technologies to increase innovation within several industries including biopharmaceuticals, fine chemicals and bio-fuels. The company was founded by Joseph M. Jacobson, George Church and Drew Endy in 2009 and is headquartered in Cambridge, MA.

Qiagen Beverly, Inc. produces reagents, kits and assays enables customers worldwide to transform patient treatment and life science research. Its products include xmal, mapl, taqiT, wgs ligase, sall, xhol and bamhi. The company was founded by Christopher Benoit and Stephen Picone in 2006 and is headquartered in Beverly, M A.

Foundation Fighting Blindness Clinical Research Institute provides investment services. The company is headquartered in Columbia, MD.

Part of University of Virginia, UVA Health Foundation operates a healthcare platform. The company is based in Charlottesville, VA.

The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.

PBM Pharmaceuticals, Inc. manufactures pharmaceutical products. The private company is based in Charlottesville, VA.

ArcherDX LLC is a genomic analysis company, which develops software solutions for investigating cancer treatment. Its products include VariantPlex, FusionPlex, LiquidPlex, reveal ctDNA, Immunoverse, custom assays, and archer analysis. The company was founded by Jason W. Myers, A. John Iafrate, and Long Phi Le on January 1, 2013 and is headquartered in Boulder, CO.

Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA.

PBM Products LLC entered into an exclusive supply arrangement to introduce the first private-label (store-brand) infant formulas in the United States. Today store-brand infant formulas have become increasingly important to retailers, and an affiliate company, PBM Nutritionals LLC manufactures state-of-the-art formulas for PBM Products and its retail partners. Whether a store brand carries its own retail name or is part of a wholesaler's private-label program, store-brand products give retailers a way to make a higher margin, differentiate themselves from the competition, and win the loyalty of customers. It believes their extensive private-label product lines are helping some of the largest retailers in America accomplish their business goals. In turn, their retail partners are helping them to accomplish its mission. PBM partners with leading food and drug retailers to provide high-quality, competitively priced products to customers labeled under the store brands of companies such as Wal-Mart, Target, Kroger, Loblaws, and Walgreens.

Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler.

Truveris, Inc. provides health information technology services. It products include TruGuard is a proprietary technology validates claim payment accuracy, ensures regulatory compliance, and manages pharmacy spend. The company was founded by Leon Greene, Anthony J. Loiacono, Thomas Andrew Staloch, Kristin Begley and Justin E. Greene in 2008 and is headquartered in New York, NY.

Genome Medical Holding Co. operates tele genomics platform which allows genetic experts to consult with patients and physicians across the country. The firm specializes in genomics, genetics, precision medicine, medical practice, personalized medicine, genetic counseling, DNA and genome. The company was founded by Lisa J. Alderson, Robert C. Green and Randal W. Scott in 2016 and is headquartered in South San Francisco, CA.

EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT.

Iantrek Inc provides biotechnology services. The company is headquartered in White Plains, NY.

Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation.

Onkos Surgical, Inc. provides surgical oncology solutions. It delivers implants and instruments that meet the needs of musculoskeletal tumor patients. The company was founded by Patrick Treacy, Antony Koblish and Adele Oliva in 2015 and is headquartered in Parsippany, NJ.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.